Inclusion Criteria:

          -  Patients must have received allogeneic hematopoietic stem cell transplant and be
             greater than 30 days post-transplant at the time of registration

          -  Patients must have documented opportunistic CMV infection, or reactivation; the
             criteria include (both of the following criteria must be met)

               -  Patients may have asymptomatic viremia (>1000 copies/ml) OR presence of symptoms
                  secondary to CMV infection, AND

               -  Patients must have ONE OF THE NEXT FOUR CRITERIA:

                    -  Absence of an improvement of viral load after ≥ 14 days of antiviral therapy
                       with ganciclovir, valganciclovir or foscarnet (decrease by at least 1 log,
                       i.e. 10-fold) or

                    -  New, persistent and/or worsening CMV-related symptoms, signs and/or markers
                       of end organ compromise while on antiviral therapy with ganciclovir,
                       valganciclovir or foscarnet, or

                    -  Have contraindications or experience adverse effects of antiviral therapy
                       with ganciclovir, valganciclovir or foscarnet.

                    -  Second recurrence of CMV viremia, CMV-related symptoms, signs and/or markers
                       of end organ compromise.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (double barrier method of birth control or abstinence) 4 weeks prior to study entry,
             for the duration of study participation and for 3 months after completing treatment.

          -  Subjects must have the ability to understand and the willingness to sign a written
             informed consent document, or assent document.

        Exclusion Criteria:

          -  Pregnant or breastfeeding women are excluded from this study.

          -  Patients with opportunistic viral infections other than CMV.

          -  Patients with active, grade 2-4, acute graft vs. host disease (GVHD), chronic GVHD or
             any condition requiring high doses of glucocorticosteroid (>0.5 mg/kg/day prednisone
             or its equivalent) as treatment

          -  Treatment with antithymocyte globulin within 28 days of planned infusion of virus -
             specific, antigen selected T cells.

          -  Treatment with virus - specific T cells within 6 weeks (42 days) of planned infusion.

        Donor eligibility

          -  Related donor of T cells must be at least partially HLA compatible, matching with
             recipient in at least 3/6 HLA loci (HLA-A, HLA-B, and HLA-DRB1 loci will be considered
             for this).

          -  Must have evidence of a serologic response (i.e. be seropositive) against CMV.

          -  Age ≥ 18 years

          -  Must meet the criteria for donor selection defined in the Standard Operating
             Procedures of University Hospitals Seidman Cancer Center Stem Cell Transplant Program

          -  Must be capable of undergoing a single standard 2 blood volume leukapheresis or
             donation of one unit of whole blood